CPMV (Mosaic ImmunoEngineering) Change In Working Capital : $0.56 Mil (TTM As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Change In Working Capital?

Mosaic ImmunoEngineering's change in working capital for the quarter that ended in Mar. 2025 was $0.13 Mil.

Mosaic ImmunoEngineering's change in working capital for the fiscal year that ended in Dec. 2024 was $0.60 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Mosaic ImmunoEngineering Change In Working Capital Historical Data

The historical data trend for Mosaic ImmunoEngineering's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering Change In Working Capital Chart

Mosaic ImmunoEngineering Annual Data

Trend

May15

May16

May17

May18

May19

May20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-0.03

1.52

1.65

0.88

0.60

Mosaic ImmunoEngineering Quarterly Data
	May20	Aug20	Nov20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															0.17	0.16	0.15	0.12	0.13

Mosaic ImmunoEngineering Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.56 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Mosaic ImmunoEngineering Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Mosaic ImmunoEngineering Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646

Website

https://www.mosaicie.com

Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.

Executives

Robert Baffi	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University	10 percent owner	10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King	director, officer: President and CEO
Paul J Lytle	director, officer: EVP, Chief Financial Officer
Robert L Garnick	director	C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz	director, officer: Chief Scientific Officer	871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry	director	315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson	director
Donald E Schrock	director	C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau	officer: VP, Business Development	MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner	officer: Chief Executive Officer	MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers	officer: Chief Financial Officer	C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick	director	6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney	officer: CFO
Helmut Jr Falk	director